Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Tax Provisions (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Tax Provisions for 5 consecutive years, with -$3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 75.76% year-over-year to -$3.9 million, compared with a TTM value of $16.9 million through Dec 2025, up 1645.46%, and an annual FY2025 reading of $16.9 million, up 1645.46% over the prior year.
  • Tax Provisions was -$3.9 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $8.7 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $11.0 million in Q4 2023 and bottomed at -$177.4 million in Q3 2022.
  • Average Tax Provisions over 5 years is -$7.6 million, with a median of $2.2 million recorded in 2022.
  • Peak annual rise in Tax Provisions hit 816.67% in 2022, while the deepest fall reached 150203.39% in 2022.
  • Year by year, Tax Provisions stood at $279000.0 in 2021, then skyrocketed by 753.05% to $2.4 million in 2022, then soared by 362.23% to $11.0 million in 2023, then tumbled by 247.47% to -$16.2 million in 2024, then soared by 75.76% to -$3.9 million in 2025.
  • Business Quant data shows Tax Provisions for KNSA at -$3.9 million in Q4 2025, $8.7 million in Q3 2025, and $5.0 million in Q2 2025.